GSK beats 2025 sales targets — but new CEO warns 2026 growth will cool
GSK forecast slower revenue growth of 3% to 5% for 2026 under new CEO Luke Miels, citing weaker vaccine and general medicines sales. Shares rose 1.4% after an initial drop. Q4 core earnings per share reached 25.5 pence, with sales up 8% to £8.62 billion. The company is reviewing cost-saving measures and manufacturing changes but has not announced immediate cuts.